Copenhagen, 2015-04-13 16:29 CEST (GLOBE NEWSWIRE) -- 13 April 2015 ─ Zealand Pharma (“Zealand”) (Nasdaq Copenhagen: ZEAL) announces an amendment to its Articles of Association to reflect an increase in the company’s share capital following exercise of employee warrants as announced in Company Announcement no. 14/2015 on 11 April 2015.
The share capital has been increased by nominal DKK 106,220 to nominal DKK 23,420,100 divided into 23,420,100 shares with a nominal value of DKK 1 each.
The amendment of Zealand’s Articles of Association entailed by the share capital increase has today been registered with the Danish Business Authority. The new Articles of Association are attached to this announcement and are also available on the company’s website: www.zealandpharma.com.
●●●●●
For further information, please contact:
Britt Meelby Jensen, President and Chief Executive Officer
Tel: +45 51 67 61 28, email: bmj@zealandpharma.com
Hanne Leth Hillman, Senior Vice President for Communications and Investor Relations
Tel: +45 50 60 36 89, email: hlh@zealandpharma.com
About Zealand Pharma
Zealand Pharma A/S (“Zealand”) (Nasdaq Copenhagen: ZEAL) is a biotechnology company based in Copenhagen, Denmark. Zealand has leading expertise in the discovery, design and development of novel peptide medicines and possesses in-house competences in clinical trial design and management with a therapeutic focus on metabolic diseases and acute care indications. The company is advancing a pipeline of novel wholly-owned medicines alongside a partnered product and development portfolio.
Zealand’s first invented medicine, lixisenatide, a once-daily prandial GLP-1 agonist for the treatment of Type 2 diabetes, is marketed globally (ex-US) as Lyxumia® and in Phase III development as a single-injection combination with Lantus® (LixiLan), both under a global license agreement with Sanofi. US regulatory submission of Lyxumia® is planned for Q3 2015 and US/EU regulatory submissions for LixiLan in Q4 2015.
Zealand’s wholly-owned products include danegaptide (prevention of Ischemic Reperfusion Injury) in Phase II and the stable glucagon product, ZP4207 (treatment of severe hypoglycemia) in Phase I as well as several preclinical peptide therapeutics. Partnering represents an important component of strategy to leverage in-house expertise, share development risk in large clinical trials, provide funding and commercialize the company’s products. Zealand currently has global license agreements and partnerships with Sanofi, Helsinn Healthcare, Boehringer Ingelheim and Eli Lilly.
For further information: www.zealandpharma.com Follow us on Twitter @ZealandPharma
